Unknown

Dataset Information

0

The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.


ABSTRACT: The therapeutic armamentarium for multiple myeloma has recently benefited from the addition of several new agents (including second-generation proteasome inhibitors, monoclonal antibodies and histone deacetylase inhibitors). This review will focus on ixazomib, an orally bioavailable second-generation proteasome inhibitor. Specifically, we will review the preclinical data, clinical trial experience, potential indications as well as unanswered questions pertaining to this new agent in multiple myeloma.

SUBMITTER: Brayer J 

PROVIDER: S-EPMC5495505 | biostudies-other | 2017 Jul

REPOSITORIES: biostudies-other

Similar Datasets

| S-EPMC7072336 | biostudies-literature
| S-EPMC7922145 | biostudies-literature
| S-EPMC8323061 | biostudies-literature
| S-EPMC4279864 | biostudies-literature
| S-EPMC7011904 | biostudies-literature
| S-EPMC4036123 | biostudies-other
| S-EPMC5135369 | biostudies-literature
2022-05-27 | PXD032030 | Pride
| S-EPMC4381198 | biostudies-literature
2021-03-06 | GSE166122 | GEO